This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
by Zacks Equity Research
eFFECTOR Therapeutics (EFTR) plunges on disappointing top-line results from the primary analysis of its mid-stage NSCLC study of tomivosertib, following the abandonment of the developmental program.
Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 814.5% in eFFECTOR Therapeutics, Inc. (EFTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
by Sanghamitra Saha
Nasdaq ETF marked first six-week rally since Jan 2020. These stocks gained more than 100% during this time frame.
Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi
by Zacks Equity Research
The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023.
Reata (RETA) Stock Jumps as FDA Approves Rare Disease Drug
by Zacks Equity Research
Skyclarys is the first drug to be approved specifically for the treatment of Friedreich's ataxia and is also Reata Pharmaceuticals' (RETA) first commercial product
Allogene (ALLO) Incurs Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Allogene's (ALLO) fourth-quarter earnings beat estimates but sales come in line.
Mirati's (MRTX) Q4 Loss Narrows, Krazati Records First Sales
by Zacks Equity Research
Mirati Therapeutics (MRTX) reports a narrower-than-expected Q4 loss and records first sales of Krazati. Stock rises in after-hours trading.
BioMarin (BMRN) Q4 Earnings Miss, Sales Beat, Stock Down
by Zacks Equity Research
BioMarin (BMRN) reports mixed Q4 results as it misses estimates for earnings but beats the same for sales. Its 2023 sales guidance falls short slightly
Moderna (MRNA) Lags on Q4 Earnings, COVID Jab Sales Down Y/Y
by Zacks Equity Research
Moderna's (MRNA) fourth-quarter earnings and sales miss expectations. Management reiterates guidance to record a minimum of $5 billion from COVID vaccine sales in 2023.
United Therapeutics (UTHR) Q4 Earnings & Sales Miss Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) fourth-quarter earnings and sales miss estimates. Tyvaso sales continue to drive the company's top line.
CRISPR (CRSP) Q4 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) fourth-quarter 2022 loss is narrower than expected, while sales miss estimates.
Biogen (BIIB) Beats Q4 Earnings & Sales Estimates, Stock Up
by Zacks Equity Research
Biogen (BIIB) beats fourth-quarter estimates for earnings and sales. Stock rises in pre-market.